Free Trial
NASDAQ:UTRS

Minerva Surgical (UTRS) Stock Price, News & Analysis

Minerva Surgical logo

About Minerva Surgical Stock (NASDAQ:UTRS)

Key Stats

Today's Range
N/A
50-Day Range
$0.0001
$0.0120
52-Week Range
N/A
Volume
1 shs
Average Volume
1,325 shs
Market Capitalization
$1,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Receive UTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Surgical and its competitors with MarketBeat's FREE daily newsletter.

UTRS Stock News Headlines

Minerva Surgical Inc.
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
Why Is Minerva Surgical (UTRS) Stock Down 50% Today?
Minerva Surgical Inc UTRS
See More Headlines

UTRS Stock Analysis - Frequently Asked Questions

Minerva Surgical, Inc. (NASDAQ:UTRS) posted its quarterly earnings data on Wednesday, December, 1st. The company reported ($23.00) EPS for the quarter, missing analysts' consensus estimates of ($8.80) by $14.20. The company had revenue of $12.51 million for the quarter, compared to analysts' expectations of $12.23 million.

Minerva Surgical's stock reverse split on Monday, October 2nd 2023. The 1-20 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Minerva Surgical (UTRS) raised $100 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

Shares of UTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Surgical investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
12/01/2021
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:UTRS
Fax
N/A
Employees
174
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$51.69 million
Book Value
$11.52 per share

Miscellaneous

Free Float
8,124,000
Market Cap
$1,000.00
Optionable
Not Optionable
Beta
3.96
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:UTRS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners